Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-CD19 4-1BB-costimulatory chimeric antigen receptor T cell therapy - Marino Biotechnology

Next Previous
X
Search
Drug Profile

Anti-CD19 4-1BB-costimulatory chimeric antigen receptor T cell therapy - Marino Biotechnology

Alternative Names: iPD1 CD19 eCAR T cells; MBC19

Latest Information Update: 28 Jul 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Marino Biotechnology
  • Developer Marino Biotechnology; Peking University
  • Class Antineoplastics; CAR-T cell therapies
  • Mechanism of Action Immunologic cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported B-cell lymphoma

Most Recent Events

  • 28 Jul 2020 No recent reports of development identified for phase-I development in B-cell lymphoma(Second-line therapy or greater) in China (Parenteral, Infusion)
  • 21 Jun 2017 Phase-I clinical trials in B-cell lymphoma (Second-line therapy or greater) in China (Parenteral) (NCT03208556)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top